OBJECTIVE: To examine the long-term effects of treatment with recombinant human CuZn superoxide dismutase (rhSOD) in infants enrolled previously in two placebo-controlled trials. STUDY DESIGN:Records for 46 (88%) infants were examined, with 19 infants having received either single or multiple intratracheal (i.t.) doses of placebo, 12 having received a single i.t. dose of rhSOD, and 15 having received multiple i.t. doses of rhSOD. Mean age at follow-up was 28 months corrected age. Records were examined for neurologic dysfunction, developmental delay, and any significant medical disorders. RESULTS: Four placebo infants (21%) had evidence of neurodevelopmental abnormalities and four infants developed asthma. Four single-dose rhSOD infants (33%) had neurodevelopmental abnormalities and two infants developed asthma. One multiple-dose rhSOD infant had evidence of neurodevelopmental abnormalities and one developed asthma. No other differences were found between the placebo and rhSOD groups. CONCLUSION: Preliminary data suggest that rhSOD is safe and not associated with any long-term adverse effects. Further results will depend on the results of multicenter trials of rhSOD in preterm infants.
RCT Entities:
OBJECTIVE: To examine the long-term effects of treatment with recombinant humanCuZn superoxide dismutase (rhSOD) in infants enrolled previously in two placebo-controlled trials. STUDY DESIGN: Records for 46 (88%) infants were examined, with 19 infants having received either single or multiple intratracheal (i.t.) doses of placebo, 12 having received a single i.t. dose of rhSOD, and 15 having received multiple i.t. doses of rhSOD. Mean age at follow-up was 28 months corrected age. Records were examined for neurologic dysfunction, developmental delay, and any significant medical disorders. RESULTS: Four placebo infants (21%) had evidence of neurodevelopmental abnormalities and four infants developed asthma. Four single-dose rhSOD infants (33%) had neurodevelopmental abnormalities and two infants developed asthma. One multiple-dose rhSOD infant had evidence of neurodevelopmental abnormalities and one developed asthma. No other differences were found between the placebo and rhSOD groups. CONCLUSION: Preliminary data suggest that rhSOD is safe and not associated with any long-term adverse effects. Further results will depend on the results of multicenter trials of rhSOD in preterm infants.
Authors: Ankur Datta; Gina A Kim; Joann M Taylor; Sylvia F Gugino; Kathryn N Farrow; Paul T Schumacker; Sara K Berkelhamer Journal: Am J Physiol Lung Cell Mol Physiol Date: 2015-06-19 Impact factor: 5.464
Authors: Satyan Lakshminrusimha; James A Russell; Stephen Wedgwood; Sylvia F Gugino; Jeffrey A Kazzaz; Jonathan M Davis; Robin H Steinhorn Journal: Am J Respir Crit Care Med Date: 2006-09-28 Impact factor: 21.405
Authors: Madathilparambil V Suresh; Bi Yu; Satyan Lakshminrusimha; David Machado-Aranda; Nicholas Talarico; Lixia Zeng; Bruce A Davidson; Subramaniam Pennathur; Krishnan Raghavendran Journal: Surgery Date: 2013-11 Impact factor: 3.982